GNE-477 was more effective at inhibiting RCC cell survival and inducing apoptosis than other PI3K-AKT-mTOR inhibitors (LY294002, AZD 2014, and Perifosine) (Ye et al., 2020). Here, MTOR is linked to renal cell carcinoma.